ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan
09 sept. 2024 10h01 HE
|
ADvantage Therapeutics, Inc.
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease,...
ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties
30 juil. 2024 12h04 HE
|
ADvantage Therapeutics, Inc.
PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists...
Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics
05 févr. 2024 09h41 HE
|
Advantage Therapeutics Inc.
BOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging,...
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease
27 nov. 2023 08h45 HE
|
Advantage Therapeutics Inc.
MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of...
Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc.
02 oct. 2023 11h12 HE
|
Advantage Therapeutics Inc.
BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc....
ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer
02 oct. 2023 10h43 HE
|
Advantage Therapeutics Inc.
ADvantage Therapeutics appoints Dr. Carmela Abraham as Chief Science Officer
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia
20 juin 2023 09h00 HE
|
Advantage Therapeutics Inc.
MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
05 avr. 2023 08h35 HE
|
Advantage Therapeutics Inc.
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics
24 mars 2023 08h45 HE
|
Advantage Therapeutics Inc.
BOCA RATON, Fla. and VIENNA, Austria, March 24, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative...
ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease
15 mars 2023 10h18 HE
|
Advantage Therapeutics Inc.
MIAMI, March 15, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...